Introduction
A ll over the world, governments face pressures of health care budget reductions while aiming at maintaining or even improving the level of service. One way to achieve these conflicting goals may be through better integration of primary and secondary care in chronic illness care and utilizing the advantages of better collaboration between general practitioners and specialists. Collaborative relationships in chronic illness care create opportunities for direct communication and information sharing that may lower barriers to care coordination. Empirical evidence suggests that the level of care coordination is positively related to clinical performance and outcomes.
1,2 Previous care coordination measures are, however, limited in their practical utility nowadays, because they involve time and cost intensive surveys that does not allow assessing the efficiency of health care systems on a large scale. 3 In the past, system-level care coordination has been impossible to measure. Recent availability of administrative data enabled researchers to develop new measures of care coordination applicable to system-level. [4] [5] [6] [7] These new measures of care coordination rely on the number of shared patients, and assume that the higher the number of shared patients, the higher the probability of developing collaborative relationships is. These new measures focus on ties in which the number of shared patients are highprovider-level care coordination measure has not been developed yet. This report fills this gap-the care coordination measure developed here has the general practitioners as providers in its focus acknowledging their role as gatekeepers and patient care coordinators.
Assessing system-level patient care coordination is as challenging as achieving it. This report takes a leap forward in providing empirical evidence for the possible impact of patient care coordination-we investigate whether the type of collaborative relationship general practitioners have built up with specialists is associated with prescription drug costs. No large-scale quantitative study has ever investigated this association. Previous research either did not develop a system-level care coordination measure, 1,2 or did not perform a provider-level analysis. 4, 6, 7 Moreover, to the authors' knowledge, this analysis shall be considered as the first attempt to measure system-level care coordination in Europe, and the second one to assess a healthcare system with universal coverage. 7 
Methods
We use prescription data for the years 2010-11 available from Doktorinfo Ltd, a health data collection and information services company based in Hungary. Twenty per cent of general practitioners practicing in Hungary feeds all their prescription into this database in real-time. General practitioners are compensated for this voluntary data provision. General practitioners in the database are representative of the entire Hungarian general practitioner population.
In this report, we focus on diabetic patients aged over 40 whose care is shared between general practitioners and specialists. Diabetic patients are defined as patients who received at least one specialist drug from the A10 'drugs used in diabetes' subgroup of the Anatomical Therapeutic Chemical Classification System-for example, insulin or an oral antidiabetic agent. In shared care, only specialists can initiate therapies with specialist medication, usually of high cost. Once specialists have initiated therapies with specialist medications, general practitioners repeat the prescription monthly, up to a maximum of 1 year. Consultations while writing repeat prescriptions allow general practitioners to filter out-and refer to specialists-cases where the health status had worsened under treatment.
The formal collaboration between general practitioners and specialists is materialized in repeat prescription of special medications by general practitioners. Similar to the recent studies, [5] [6] [7] collaborative relationship between two doctors exists if they care for at least one patient together.
This information is readily and unambiguously available from the prescription data, where the identification numbers of prescribing general practitioners and therapy-initiating specialists both appear on prescriptions.
The structure of collaborative relationships between general practitioners and specialists depends on both the number of specialists with whom general practitioners coordinate care and patient distribution across specialists. General practitioners channelling the majority of their patients to a few specialists build up strong, collaborative relationship with specialists, whereas general practitioners channelling their patients to many specialists build up weak, fragmented collaborative ties. The structure of collaborative relationships between general practitioners and specialists is measured by the Herfindahl-Hirschman Index (HHI), the sum of the squares of the proportion of general practitioner's patients shared with specialists. 8 The higher the index, the more concentrated the collaborative structure of general practitioners, which implies stronger collaborative relationships among doctors. General practitioners build up strong collaborative relationship with specialists, if the HHI is in the uppermost decile; if HHI is in the lowest decile then general practitioners have weak, fragmented ties with specialists.
In a bivariate analysis, we first test whether the type of collaborative structure (strong vs. fragmented) is associated with prescription drug costs. Prescription drug costs are measured as the sum of the retail prices for drugs prescribed by general practitioners. In a multivariate regression analysis, potentially confounding variables are controlled for-the variation in prescription drug costs across the patient lists of general practitioners is explained by the type of collaborative structure and potentially important patient characteristics such as age, diagnosis-based comorbidity index and type of treatment.
To test the robustness of the findings settlement size is used as a moderator variable: we investigate whether the significant relationship between the strengths of collaborative relationships and prescription drug cost is independent from settlement size, and thus from the supply of specialists.
Results
The final sample includes 794 general practitioners and 318 specialists in endocrinology who shared care for 31 070 diabetic patients. Over the 2-year sample period general practitioners issued 509 281 specialist medication prescriptions for antidiabetic agents and wrote an additional 3 575 726 prescriptions. A typical GP treated 39 diabetic patients and wrote 1060 prescriptions for antidiabetic agents-14 prescriptions per patient per year. On average, a general practitioner coordinated care with eight specialists.
The bivariate analysis shows that the type of collaborative structure affects prescription drug costs-they are 5.88% lower for patients treated by general practitioners who build up strong collaborative relationships with specialists than for patients treated by general practitioners who are connected to specialists with weak, fragmented ties (587 vs. 623 thousand Hungarian Forint, P < 0.00000). The multivariate analysis confirms that the type of collaborative structure is a statistically significant determinant of prescription drug costs (table 1) . In addition to the type of collaborative structures, both the treatment method and the presence of diabetes complications are an important determinant of prescription drug costs-patients treated by the generally more expensive insulin and patients who have diabetes complications involve significantly higher prescription drug costs.
One might argue that in small settlements, where the supply of specialists is smaller, general practitioners naturally build up strong collaborative relationships, whereas in large settlements the opposite can be observed. Using settlement size as moderator variable, our results remained practically unchanged-prescription drug costs were significantly lower in all three subsamples split by settlement size.
Discussion
Both bivariate and multivariate analyses confirm that prescription drug costs for patients treated by general practitioners who build up strong collaborative relationships with specialists are significantly lower than for patients treated by general practitioners characterized by fragmented collaborative structures, a major benefit for the society as a whole. This finding is in line with previous literature reporting that better care coordination is associated with lower health utilization, including lower hospitalization and fewer emergency visits. 4, 6, 7 This article finds empirical evidence for this association at system level for primary care providers-association never tested in the literature before.
The current research is limited by sampling bias (voluntary data provision), assessing only prescription drug costs, and focusing only on diabetic patients in Hungary. As such, it suggests several opportunities for future research. Most importantly, the findings shall be confirmed in numerous other settings (countries, specialities, cost elements); for complex, physician collaboration networks multilevel regression analyses are suggested. 10 Additional limitations include the proxy used for collaboration, incomplete diagnoses data, and disregarding patients' perception and satisfaction.
This study might bear important policy implications with regard to care fragmentation-general practitioners may struggle to coordinate care, if they should collaborate with more specialists, and prescription drug costs would be higher. If future research shows that healthcare costs are indeed lower for patients treated in strong collaborative structures in numerous other settings, then healthcare strategists need to advocate a healthcare system with lower care fragmentation. Lower care fragmentation might be achieved either through offering patients limited rather than unrestricted choice in secondary care or through providing financial incentives for general practitioners who build up strong collaborative relationships with specialists. Lower care fragmentation, coupled with enhanced medical education and technical infrastructure might benefit patients, by savings on travel times and costs, and the wider society, by savings on healthcare costs.
In chronic illness care, a provider-level care coordination measure is useful for testing whether the type of collaborative structures in primary care is associated with drug costs. Prescription drug costs for patients treated by general practitioners who build up strong collaborative relationships with specialists are significantly lower than for patients treated by general practitioners characterized by fragmented collaborative structures. If future system-level studies confirm that total healthcare costs are indeed lower for patients treated in strong collaborative structures, then healthcare strategists need to advocate a healthcare system with lower care fragmentation on the interface of primary and secondary care. Regulating access to secondary care, either through limiting choice or through financial incentives provided to general practitioners, might result in significant cost savings. 
.408. a: The Quan-modified Charlson comorbidity index is a diagnosis-based comorbidity measure. 9 International Classification of Diseases (ICD-10) codes written on the prescriptions are employed to identify which of the comorbid conditions apply to the patients in the sample. 
Introduction
A pproximately 1 million divorces are recorded every year in Europe 1 and another 850 000 in the USA. 2 It is estimated that slightly more than half of all divorces involve children under the age of 18. 3 In addition, an increasing number of parents are not officially married, 1 and if they break up, their children face similar life changes as children of married parents getting a divorce. Parental break-up is in most cases due to long-term conflicts in the family, and the detrimental effects of divorce and the underlying conflicts on the mental well-being of children are well documented. 4, 5 Considering that stress in childhood and early puberty is found to be a risk factor for later mental health disorders, 6 -8 the high number of children experiencing parental break-up constitute a particular public health concern. Hence, it is important to identify vulnerable children who may require extra support, and identify protective factors that may mitigate the negative effects of parental break-up.
Age at parental break-up might be an important factor when considering vulnerability to stress in children. [9] [10] [11] [12] [13] [14] [15] [16] [17] The first years of life is a period characterized by rapid development of physical, social and mental abilities; a process where the family environment plays a crucial role. 18 Both classical psychological theory as well as neuropsychological research has emphasized caregiving and attachment in the first years of life as important for both physical and mental development in general, 19 as well as for the development of stress specific systems such as regulations of cortisol levels. 20, 21 As the effect of divorce and parental conflicts on children's mental
